Synergy Wellness and MediSpa, PC
Synergy Wellness and MediSpa, PC · 700 Oceanport Avenue · Oceanport, NJ 07757
4.7· 216 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Synergy Wellness and MediSpa, PC is a medical spa in Oceanport, New Jersey, whose website highlights aesthetic services including CoolSculpting and injectables; weight-loss care is also listed for the practice. The site names Nestor Restua, MD, and Christopher Valerian, DO. On Google it holds a 4.7-star rating across 216 reviews dating to 2024, with 46 posted in the past year. Reviewers most often mention the staff and the providers' knowledge, 19 reviews mention results, and 10 mention scheduling.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-18. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.7 across 216 Google reviews. Of the 100 reviews we analyzed, 98 (98%) are positive (4–5★) and 1 (1%) are negative (1–2★).
What patients like
- Friendly, helpful staff41 reviews
- Knowledgeable, professional providers27 reviews
- Weight-loss results18 reviews
- Easy scheduling and communication10 reviews
Common complaints
Very few complaints — only 1 negative review, with no recurring theme.
Most recent Google reviews
sabrina l.★★★★★2026-09-18Rhianna is seriously the BEST\!\! I wouldn’t trust anyone else with my face\. She is so knowledgeable, attentive, and truly takes the time to understand exactly what you want while still giving honest recommendations\. I always feel completely comfortable in her hands, and my results are always so natural and beautiful\. She has such a great eye for detail and somehow makes me look refreshed without ever looking overdone\. On top of being incredibly talented, she is the sweetest and makes every appointment such a great experience\. I recommend Rhianna to everyone — if you’re thinking about getting Botox, GO SEE HER\!\! 🤍
Abby Z.★★★★★2026-09-17Rhianna is the best!! She’s done my lip filler twice and they look so good each time, I love them!! Definitely go to her for the best filler and Botox!!
Jennifer M.★★★★★2026-09-17Rhianna is the absolute best! I love that she’s a registered nurse, fully listens and takes her time to explain all. The spa itself is clean and beautiful.
Lexi★★★★★2026-09-14Went to synergy to get a facial done with Skyla and she was so amazing, she was so gentle, gave my face an amazing massage, and made my skin look like glass! Made me feel so comfortable and relaxed will definitely be coming back to Skyla!
Emily M.★★★★★2026-09-08Danielle and entire staff are so amazing - knowledgeable and kind. Beautiful new offices!!!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs